ALDH1A1 and ALDH3A1 expression in lung cancers: correlation with histologic type and potential precursors.

We hypothesize that aldehyde dehydrogenase (ALDH) isozymes may be upregulated in lung tissue as a result of exposure to carcinogenic aldehydes found in cigarette smoke. To investigate this hypothesis, we studied the expression of two ALDH isozymes in lung cancer from patient samples and its relationship to the history of cigarette smoking. Immunohistochemical staining for ALDH1A1 and ALDH3A1 was performed on archival specimens from control patients without lung cancer, and patients with one of the primary lung cancers: squamous cell cancer (SCCA), adenocarcinoma (AdenoCA), and small cell lung cancer (SCLC). An overall score was obtained for each sample based upon multiplying the staining intensity (0-3) and the extensiveness (0-100%). Mean+/-S.E.M. for each experimental group was calculated and compared. Our results indicate a significantly higher level of expression of ALDH1A1 and ALDH3A1 in SCCA (155+/-19 and 162+/-17, respectively) and AdenoCA (116+/-12 and 107+/-10) than SCLC (39+/-11 and 42+/-12) (P<0.01). Atypical pneumocytes demonstrated significantly higher levels of expression of ALDH1A1 and ALDH3A1 than normal pneumocytes (a normal counterpart of AdenoCA), which is suggestive of up regulation during malignant transformation to AdenoCA. A subset analysis of all samples studied revealed increased expression of ALDH1A1 (P=0.055) and ALDH3A1 (P=0.0093) in normal pneumocytes of smokers (n=32) in comparison to those of non-smokers (n=17). Non-small cell lung cancer (NSCLC) express very high levels of ALDH1A1 and ALDH3A1 in comparison with SCLC, elevated expression of both enzymes may be associated with malignant transformation to AdenoCA, and cigarette smoking seems to result in increased expression of these enzymes in normal pneumocytes.

[1]  L. Sreerama,et al.  Relative contribution of human erythrocyte aldehyde dehydrogenase to the systemic detoxification of the oxazaphosphorines. , 1997, Drug metabolism and disposition: the biological fate of chemicals.

[2]  S. Shammah,et al.  Induction of cyclophosphamide-resistance by aldehyde-dehydrogenase gene transfer. , 1996, Blood.

[3]  Diana Anderson,et al.  Genetic effects of ethanol , 1987 .

[4]  F. Chung,et al.  Detection of 1, N2-propanodeoxyguanosine adducts as potential endogenous DNA lesions in rodent and human tissues. , 1996, Cancer research.

[5]  F. Chytil.  Retinoids in lung development , 1996, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[6]  T. Koivula,et al.  Comparison of phenobarbital- and carcinogen-induced aldehyde dehydrogenases in the rat. , 1979, Biochimica et Biophysica Acta.

[7]  L. Sreerama,et al.  Identification and characterization of a novel class 3 aldehyde dehydrogenase overexpressed in a human breast adenocarcinoma cell line exhibiting oxazaphosphorine-specific acquired resistance. , 1993, Biochemical pharmacology.

[8]  V. Vasiliou,et al.  Role of aldehyde dehydrogenases in endogenous and xenobiotic metabolism. , 2000, Chemico-biological interactions.

[9]  O. Colvin,et al.  Isolation of primitive human hematopoietic progenitors on the basis of aldehyde dehydrogenase activity. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[10]  Y. Ohno,et al.  Formation, toxicity and inactivation of acrolein during biotransformation of cyclophosphamide as studied in freshly isolated cells from rat liver and kidney , 1985, Archives of Toxicology.

[11]  A. Townsend,et al.  De Novo Expression of Transfected Human Class 1 Aldehyde Dehydrogenase (ALDH) Causes Resistance to Oxazaphosphorine Anti-cancer Alkylating Agents in Hamster V79 Cell Lines , 1996, The Journal of Biological Chemistry.

[12]  K. Lindahl-Kiessling,et al.  Increased frequency of acetaldehyde-induced sister-chromatid exchanges in human lymphocytes treated with an aldehyde dehydrogenase inhibitor. , 1991, Mutation research.

[13]  R. Lindahl,et al.  Changes in aldehyde dehydrogenase activity during diethylnitrosamine- or 2-acetylaminofluorene-initiated rat hepatocarcinogenesis. , 1983, Cancer research.

[14]  J. Trent,et al.  α-methylacyl-CoA racemase: A new molecular marker for prostate cancer , 2002 .

[15]  Lakshmaiah Sreerama,et al.  Cellular levels of aldehyde dehydrogenases (ALDH1A1 and ALDH3A1) as predictors of therapeutic responses to cyclophosphamide-based chemotherapy of breast cancer: a retrospective study , 2002, Cancer Chemotherapy and Pharmacology.

[16]  V. Feron,et al.  Aldehydes: occurrence, carcinogenic potential, mechanism of action and risk assessment. , 1991, Mutation research.

[17]  J. H. Carter,et al.  Hepatocyte expression of tumor associated aldehyde dehydrogenase (ALDH-3) and p21 Ras following diethylnitrosamine (DEN) initiation and chronic exposure to di(2-ethylhexyl)phthalate (DHEP). , 1996, Carcinogenesis.

[18]  C. Manthey,et al.  Identification of the mouse aldehyde dehydrogenases important in aldophosphamide detoxification. , 1990, Cancer research.

[19]  P. Shields.  Epidemiology of tobacco carcinogenesis , 2000, Current oncology reports.

[20]  R. Smith,et al.  Detection of 1,N6-propanodeoxyadenosine in acrolein-modified polydeoxyadenylic acid and DNA by 32P postlabeling. , 1990, Cancer research.

[21]  S. Salani,et al.  Identification of a Primitive Brain–Derived Neural Stem Cell Population Based on Aldehyde Dehydrogenase Activity , 2006, Stem cells.

[22]  M. A. Pereira,et al.  Aldehyde dehydrogenase as a marker for chemically initiated mouse liver tumors. , 1986, Cancer Letters.

[23]  D. Clarke,et al.  Blockage of drug resistance in vitro by disulfiram, a drug used to treat alcoholism. , 2000, Journal of the National Cancer Institute.

[24]  D. Agarwal,et al.  Detoxification of cyclophosphamide by human aldehyde dehydrogenase isozymes. , 1994, Cancer letters.

[25]  S. Janes,et al.  Lung cancer and lung stem cells: strange bedfellows? , 2007, American journal of respiratory and critical care medicine.

[26]  Anders Isaksson,et al.  Pharmacological profiling of disulfiram using human tumor cell lines and human tumor cells from patients. , 2007, Biochemical pharmacology.

[27]  N. Sládek,et al.  Restoration of sensitivity to oxazaphosphorines by inhibitors of aldehyde dehydrogenase activity in cultured oxazaphosphorine-resistant L1210 and cross-linking agent-resistant P388 cell lines. , 1985, Cancer research.

[28]  G. Duester,et al.  Molecular analysis of two closely related mouse aldehyde dehydrogenase genes: identification of a role for Aldh1, but not Aldh-pb, in the biosynthesis of retinoic acid. , 1999, The Biochemical journal.

[29]  G. Pond,et al.  Phase II study of pegylated liposomal doxorubicin HCl (Caelyx) in combination with cyclophosphamide and vincristine as second-line treatment of patients with small cell lung cancer. , 2003, Lung cancer.

[30]  Y. Koutalos,et al.  Human Aldehyde Dehydrogenase 3A1 Inhibits Proliferation and Promotes Survival of Human Corneal Epithelial Cells* , 2005, Journal of Biological Chemistry.

[31]  V. Vasiliou,et al.  Effect of various chemicals on the aldehyde dehydrogenase activity of the rat liver cytosol. , 1991, Chemico-biological interactions.

[32]  J. Hilton.  Role of aldehyde dehydrogenase in cyclophosphamide-resistant L1210 leukemia. , 1984, Cancer research.

[33]  E. Marinelli,et al.  Synthesis of 1,N2-(1,3-propano)-2'-deoxyguanosine and incorporation into oligodeoxynucleotides: a model for exocyclic acrolein-DNA adducts. , 1990, Chemical research in toxicology.

[34]  T. Jacks,et al.  Identification of Bronchioalveolar Stem Cells in Normal Lung and Lung Cancer , 2005, Cell.

[35]  Daniel F. Brayton,et al.  Disulfiram facilitates intracellular Cu uptake and induces apoptosis in human melanoma cells. , 2004, Journal of medicinal chemistry.

[36]  D. Dréau,et al.  Disulfiram inhibits activating transcription factor/cyclic AMP-responsive element binding protein and human melanoma growth in a metal-dependent manner in vitro, in mice and in a patient with metastatic disease. , 2004, Molecular cancer therapeutics.

[37]  S. Biswal,et al.  Acrolein Causes Inhibitor κB-independent Decreases in Nuclear Factor κB Activation in Human Lung Adenocarcinoma (A549) Cells* , 1999, The Journal of Biological Chemistry.

[38]  A. Berns.  Stem Cells for Lung Cancer? , 2005, Cell.

[39]  R. Lindahl,et al.  Expression of the tumor aldehyde dehydrogenase phenotype during 2-acetylaminofluorene-induced rat hepatocarcinogenesis. , 1982, Cancer research.

[40]  D. Mohuczy,et al.  Retinoic Acid Down-Regulates Aldehyde Dehydrogenase and Increases Cytotoxicity of 4-Hydroperoxycyclophosphamide and Acetaldehyde , 2005, Journal of Pharmacology and Experimental Therapeutics.

[41]  O. Hänninen,et al.  Induction of aldehyde dehydrogenase by polycyclic aromatic hydrocarbons in rats. , 1981, Chemico-biological interactions.

[42]  M. Schweder,et al.  Overexpression of the human aldehyde dehydrogenase class I results in increased resistance to 4-hydroperoxycyclophosphamide. , 1996, Cancer gene therapy.

[43]  J. Piatigorsky,et al.  Role of aldehyde dehydrogenase isozymes in the defense of rat lens and human lens epithelial cells against oxidative stress. , 2005, Investigative ophthalmology & visual science.

[44]  R. Deitrich,et al.  Induction of different rat liver supernatant aldehyde dehydrogenases by phenobarbital and tetrachlorodibenzo-p-dioxin. , 1977, The Journal of biological chemistry.

[45]  G. Zimmerman,et al.  Molecular Cloning of a Novel Human Diacylglycerol Kinase Highly Selective for Arachidonate-containing Substrates (*) , 1996, The Journal of Biological Chemistry.

[46]  L. Sreerama,et al.  Human breast adenocarcinoma MCF-7/0 cells electroporated with cytosolic class 3 aldehyde dehydrogenases obtained from tumor cells and a normal tissue exhibit differential sensitivity to mafosfamide. , 1995, Drug metabolism and disposition: the biological fate of chemicals.

[47]  Q Ping Dou,et al.  Disulfiram, a clinically used anti-alcoholism drug and copper-binding agent, induces apoptotic cell death in breast cancer cultures and xenografts via inhibition of the proteasome activity. , 2006, Cancer research.

[48]  M. Schweder,et al.  Expression of antisense RNA to aldehyde dehydrogenase class-1 sensitizes tumor cells to 4-hydroperoxycyclophosphamide in vitro. , 2000, The Journal of pharmacology and experimental therapeutics.

[49]  J. Moreb,et al.  RNAi-mediated knockdown of aldehyde dehydrogenase class-1A1 and class-3A1 is specific and reveals that each contributes equally to the resistance against 4-hydroperoxycyclophosphamide , 2006, Cancer Chemotherapy and Pharmacology.

[50]  J. Moreb,et al.  Heterogeneity of aldehyde dehydrogenase expression in lung cancer cell lines is revealed by Aldefluor flow cytometry‐based assay , 2007, Cytometry. Part B, Clinical cytometry.

[51]  R. Deitrich,et al.  Induction of aldehyde dehydrogenases. , 1978, Biochemical pharmacology.

[52]  N. Sládek.  Human aldehyde dehydrogenases: Potential pathological, pharmacological, and toxicological impact , 2003, Journal of biochemical and molecular toxicology.

[53]  L. Sreerama,et al.  Class 1 and class 3 aldehyde dehydrogenase levels in the human tumor cell lines currently used by the National Cancer Institute to screen for potentially useful antitumor agents. , 1997, Advances in experimental medicine and biology.

[54]  T. Dragani,et al.  Downexpression of aldehyde dehydrogenase 1 in murine lung tumors , 1996, Molecular carcinogenesis.

[55]  V. Vasiliou,et al.  Aldehyde dehydrogenase gene superfamily: the 2000 update. , 2001, Chemico-biological interactions.

[56]  L. Sreerama,et al.  Intrinsic cellular resistance to oxazaphosphorines exhibited by a human colon carcinoma cell line expressing relatively large amounts of a class-3 aldehyde dehydrogenase. , 1994, Biochemical pharmacology.